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Low-Level Transcutaneous Electrical Vagus Nerve 
Stimulation (LLTS) Suppresses Atrial Fibrillation 
Patients with paroxysmal atrial fibrillation (AF) were 
randomized to 1 hour of 20 Hz LLTS (n=20) or sham control 
(n=20) by attaching a flat metal clip onto the tragus in the 
right ear. AF was induced by burst atrial pacing at baseline 
and after 1 hour of LLTS or sham treatment. Blood samples 
from the coronary sinus and the femoral vein were collected 
at those time points and analyzed for inflammatory cytokines, 
including tumor necrosis factor alpha and C-reactive protein. 
Pacing-induced AF duration decreased significantly by 6.3±1.9 
min compared with baseline in the LLTS but not in the control 
group (p=0.002). AF cycle length increased significantly from 
baseline by 28.8±6.5 ms in the LLTS but not in the control 
group (p=0.0002). Femoral vein but not coronary sinus tumor 
necrosis factor (TNF)-alpha and C-reactive protein levels 
decreased significantly only in the LLTS group. The authors 
concluded that LLTS suppresses AF and decreases inflamma-
tory cytokines in patients with paroxysmal AF, supporting a 
role of neuromodulation to treat AF (Stavrakis S et al, J Am 
Coll Cardiol 2015;65:867-875).
Among Patients with Early Repolarization Syndrome, 
Programmed Stimulation Does not Predict Future 
Arrhythmic Events
In a multicenter study, 81 patients, aged 36±13 years, 
with early repolarization (ER) syndrome and aborted sud-
den death due to ventricular fibrillation (VF) underwent an 
electrophysiology study (EPS). VF was inducible in only 18 
of 81 (22%) patients. During follow-up of 7.0±4.9 years, 6 
of 18 (33%) patients with inducible VF, and 21 of 63 (33%) 
noninducible patients experienced VF recurrences (p=NS). VF 
storm occurred in 3 inducible and 4 noninducible patients. VF 
inducibility was not associated with maximum J-wave amplitude 
or J-wave distribution (inferior, odds ratio -OR: 0.96; lateral, 
OR: 1.57; inferior and lateral, OR: 0.83; all p=NS), which 
have previously been shown to predict outcome in patients 
with an ER pattern. The authors concluded that EPS did not 
enhance risk stratification in ER syndrome (Mahida S et al, J 
Am Coll Cardiol 2015;65:151-159). 
ICD Therapy is an Effective Strategy in Patients  
With Brugada Syndrome, Treating Potentially  
Lethal Arrhythmias in 17% of Patients but also  
in 13% of Asymptomatic Patients, Albeit  
at Increased Risk for Complications in 16% /  
Risk Stratification by Means of EPS Might  
Identify Asymptomatic Patients at Risk 
Among 176 consecutive Brugada syndrome patients, spon-
taneous sustained ventricular arrhythmias (VAs) occurred in 
30 patients (17%) at follow-up of 7±4.8 years. Eight patients 
(4.5%) died. Appropriate ICD shocks occurred in 28 (15.9%), 
inappropriate shocks in 33 patients (18.7%), and electrical 
storm in 4 (2.3%). Device-related complications occurred in 
28 patients (15.9%). In multivariate analysis, aborted sudden 
cardiac death and VA inducibility on electrophysiology stud-
ies (EPS) were independent predictors of appropriate shock 
occurrence. The authors concluded that ICD therapy was 
an effective strategy in Brugada syndrome, treating poten-
tially lethal arrhythmias in 17% of patients during long-term 
follow-up, but also in 13% of asymptomatic patients. Risk 
stratification by EPS may identify asymptomatic patients at 
risk for arrhythmic events. ICDs are frequently associated 
with device-related complications (Conte G et al, J Am Coll 
Cardiol 2015;65:879–888). 
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Swedish Registries: Benefit of Anticoagulation  
Unlikely in Patients With Atrial Fibrillation (AF)  
and a CHA2DS2-VASc Score of 1
According to a retrospective study of 140,420 patients with 
AF, among those with a CHA2DS2-VASc score of 1, the annual 
event rates varied between 0.5% and 0.9%; women were truly 
low risk, with an annual ischemic stroke rate of only 0.1% to 
0.2%. For men, the ischemic stroke rate was between 0.5% 
and 0.7%. When the endpoint included diagnoses of TIA, pul-
monary embolism, arterial embolism, and stroke not specified 
as ischemic or hemorrhagic, the annual event rate for men was 
1.3%. The authors concluded that the risk of ischemic stroke 
in patients with AF and a CHA2DS2-VASc score of 1 seems to 
be lower than previously reported (Friberg L et al, J Am Coll 
Cardiol 2015;65:225–32). 
Taiwanese Study: Anticoagulation Should  
be Considered for AF Patients With  
1 Additional Stroke Risk Factor Given their  
High Risk of Ischemic Stroke 
A retrospective study investigated the risk of ischemic 
stroke in patients with a single additional stroke risk factor, 
i.e., CHA2DS2-VASc score=1 (males) or 2 (females). Among 
12,935 male AF patients with a CHA2DS2-VASc score of 1, 
1,858 patients (14.4%) had an ischemic stroke during follow-
up (5.2±4.3 years), with an annual stroke rate of 2.75%. 
Ischemic stroke risk ranged from 1.96%/year for men with 
vascular disease to 3.5%/year for those 65 to 74 years of age. 
For 7,900 females with AF and a CHA2DS2-VASc score of 2, 
14.9% experienced ischemic stroke for an annual stroke rate 
of 2.55%. Ischemic stroke risk increased from 1.91%/year for 
women with hypertension to 3.34%/year for those 65 to 74 
years of age. The authors concluded that among risk factors, 
age 65 to 74 years is associated with the highest stroke rate. 
Oral anticoagulation should be considered for AF patients with 
1 additional stroke risk factor given their high risk of ischemic 
stroke (Chao T et al, J Am Coll Cardiol 2015;65:635–642). 
ITALIC Trial: Bleeding and Thrombotic Event  
Rates Not Different Between 6- & 24-Month  
DAPT After PCI with 2nd-Generation  
DES/6-Month DAPT Non-inferior to 24-Month  
DAPT in Good Aspirin Responders 
Of 2,031 enrolled patients undergoing implantation of 
everolimus-eluting stents with confirmed nonresistance to 
aspirin, 941 patients were randomized to 24-month and 953 
to 6-month dual antiplatelet therapy (DAPT). The primary 
endpoint (death, myocardial infarction, urgent target vessel 
revascularization, stroke, and major bleeding at 12 months 
post-stenting) was no different (24-month: 1.5% vs 6-month: 
1.6%; p=NS). 6-month was noninferior to 24-month DAPT. 
There were no significant differences in stent thrombosis or 
bleeding complications. In the 792 (44%) high-risk patients with 
ACS, primary and secondary endpoints did not significantly 
differ (hazard ratio: 1.7; p=NS). The authors concluded that 
rates of bleeding and thrombotic events were not significantly 
different according to 6- vs 24-month DAPT after PCI with 
new-generation DES in good aspirin responders (Gilard M et 
al, J Am Coll Cardiol 2015;65:777–786).
Meta-Analysis: Short-Term (≤6 Months) Dual 
Antiplatelet Therapy (DAPT) After Implantation of 
Drug-Eluting Stents Produced Similar Rates of Major 
Adverse Cardiac Events (MACE) But Significantly 
Less Bleeding Than Longer-Term (≥1 Year) DAPT 
Metaanalysis of 4 randomized trials including 8,180 patients 
indicated that at 1-year, short-term (≤6 months) DAPT was 
associated with similar rates of MACE (hazard ratio - HR: 
1.11; p=NS), but significantly lower rates of bleeding (HR: 
0.66; p=0.03) versus prolonged DAPT (1 year). Comparable 
results were apparent between DAPT discontinuation and 
1-year follow-up (for MACE: HR: 1.20; p=NS) (for bleed-
ing: HR: 0.44; p=0.03). There were no significant differences 
in 1-year rates of MACE among 3-month vs 1-year DAPT, 
6-month vs 1-year DAPT, or 3-month vs 6-month DAPT. 
The authors concluded that compared with prolonged DAPT, 
short-term DAPT is associated with similar rates of MACE 
but lower rates of bleeding after DES placement (Palmerini 
T et al, J Am Coll Cardiol 2015;65:1092-1102).
Occupational Health Hazards of Working  
in the Interventional Laboratory: More  
Work-Related Musculoskeletal Pain but No Cancer
Among 1,543 Mayo Clinic employees (aged 43±11.3 years, 
33% male) working in interventional cardiology or radiology 
laboratories responding (57%) to a survey, 1,042 (67.5%) were 
involved with procedures utilizing radiation. They reported 
experiencing work-related pain more often than the control 
group before (54.7% vs 44.7%; p<0.001) and after adjust-
ment for confounding factors (odds ratio: 1.67; p<0.001). 
Musculoskeletal pain varied significantly by job description, 
with the highest incidence reported by technicians (62%) and 
nurses (60%) followed by physicians (44%) and trainees (19%; 
p<0.001). There was no difference in cancer prevalence be-
tween groups (9% vs 9%) (Orme NM et al, J Am Coll Cardiol 
2015;65:820-826). 
Circulating Levels of Amyloid Beta are Predictive  
of Cardiovascular Mortality in Patients With 
Established Coronary Heart Disease (CHD) 
Amyloid beta peptide, a major protein constituent of 
neuritic plaques in Alzheimer disease, with a central role in 
vascular inflammation pathophysiology, was measured (amy-
loid beta 40 form: Abeta40) in blood samples collected from 
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1,464 patients with CHD. Abeta40 independently predicted 
cardiovascular (CV) death and major adverse cardiac events 
(MACE) in patients with CHD (p<0.05 for all). Cohort-based 
analysis revealed that Abeta40 levels were significantly and 
independently associated with arterial stiffness progression, 
incident subclinical atherosclerosis and CHD. The authors 
concluded that measuring blood levels of Abeta40 identified 
patients at high risk for CV death. (Stamatelopoulos K et al, 
J Am Coll Cardiol 2015;65:904-916).
Cvlprit: In Patients Undergoing Primary-PCI  
for STEMI, Complete Revascularization  
During Index Admission Confers Significantly  
Fewer MACE at 12 Months Than When Only  
the IRA is Treated
In CvLPRIT (Complete versus Lesion-only Primary PCI 
trial), 296 patients with STEMI undergoing primary PCI (P-
PCI) in 7 UK centers were randomized to either in-hospital 
complete revascularization (either at the time of P-PCI or 
before hospital discharge) (n=150) or infarct-related artery 
(IRA)-only revascularization (n=146). The primary endpoint 
(all-cause death, recurrent myocardial infarction -MI, heart fail-
ure, and ischemia-driven revascularization within 12 months), 
but not death or MI, was reduced with complete compared with 
IRA-only revascularization (10% vs 21.2%; hazard ratio: 0.45; 
p=0.009). A trend toward benefit was seen early after complete 
revascularization (p=0.055 at 30 days). The authors concluded 
that in patients presenting for P-PCI with multivessel disease, 
index admission complete revascularization significantly low-
ered the rate of the composite primary endpoint at 12 months 
compared with treating only the IRA (Gershlick AH et al, J 
Am Coll Cardiol 2015;65:963-972). N.B. The 2 randomized 
trials, PRAMI & CvLPRIT, reporting reduced MACE for 
PCI on non–infarct-related stenotic coronary arteries, have 
led to withdrawal of class III practice guideline recommen-
dations not to treat significant non–infarct-related stenoses 
in patients with STEMI and multivessel disease undergoing 
primary angioplasty.
PARADIGM-HF: Angiotensin Receptor Neprilysin 
Inhibition Compared With Enalapril Reduces the Risk 
of Clinical Progression in Surviving Patients With 
Heart Failure 
Therapy with angiotensin-neprilysin inhibitor LCZ696 
(400 mg daily) compared with enalapril (20 mg daily) in 8399 
patients with heart failure and reduced ejection fraction led to 
fewer patients needing intensification of anticongestive treat-
ment (520 vs 604; hazard ratio-HR, 0.84; P=0.003) or visiting 
the emergency room for worsening heart failure (HR, 0.66; 
P=0.001). The LCZ696 group had 23% fewer hospitalizations 
for worsening heart failure (P<0.001) (evident within the first 
30 days) and were less likely to require intensive care (18% 
rate reduction, P=0.005), to receive inotropic agents (31% 
risk reduction, P<0.001), and to have implantation of a heart 
failure device or cardiac transplantation (22% risk reduction, 
P=0.07). LCZ696 led to an early and sustained reduction in 
biomarkers of myocardial wall stress and injury (N-terminal 
pro–B-type natriuretic peptide and troponin) vs enalapril. 
The authors concluded that angiotensin-neprilysin inhibition 
prevents clinical progression of surviving patients with heart 
failure more effectively than angiotensin-converting enzyme 
inhibition (Packer M et al, Circulation 2015;131:54-61).
ORBIT-AF: Bridging Anticoagulation is Associated 
With Higher Risk of Bleeding and Adverse Events
The Outcomes Registry for Better Informed Treatment of 
Atrial Fibrillation (ORBIT-AF) recorded temporary interrup-
tions of oral anticoagulation for a procedure. Of 7372 patients 
treated with oral anticoagulation, 2803 overall interruption 
events occurred in 2200 patients (30%) at a median of 2 years. 
Bridging was used in 24% (n=665), mostly with low-molecular 
weight heparin (73%, n=487) and unfractionated heparin 
(15%, n=97). Bridged patients were more likely to have had 
prior cerebrovascular events (22% vs 15%; P=0.0003) and 
mechanical valves (9.6% vs 2.4%; P<0.0001); however, there 
was no difference in CHA2DS2-VASc scores (scores ≥2 in 94% 
vs 95%; P=0.5). Bleeding events were more common in bridged 
than non-bridged patients (5% vs 1.3%; odds ratio-OR, 3.84; 
P<0.0001). The incidence of myocardial infarction, stroke or 
systemic embolism, major bleeding, hospitalization, or death 
within 30 days was also significantly higher in patients receiving 
bridging (13% vs 6.3%; OR, 1.94; P=0.0001) (Steinberg PA 
et al, Circulation 2015;131:488-494).
Meta-Analysis for Myocardial Infarction (MI) With 
Nonobstructive Coronary Arteries (MINOCA): 6% 
Prevalence / More Likely in Younger and Female 
Patients and with Lower All-Cause Mortality at 12 
Months (4.7% vs 6.7%) Compared With MI With 
Obstructive Coronary Artery Disease 
According with a meta-analysis of 28 publications, the 
prevalence of MINOCA was 6% with a median patient age of 
55 years and 40% women. However, in comparison with those 
with MI associated with obstructive coronary artery disease, 
patients with MINOCA were more likely to be younger and 
female but less likely to have hyperlipidemia. All-cause mor-
tality at 12 months was lower in MINOCA compared with 
MI associated with obstructive coronary artery disease (4.7% 
vs 6.7%). Typical MI on cardiac magnetic resonance imaging 
is found in only 24% of patients, myocarditis in 33% and no 
significant abnormality in 26%. Coronary artery spasm was 
inducible in 27% of MINOCA patients, and thrombophilia 
disorders were detected in 14% (Pasupathy S et al, Circulation 
2015;131:861-870).
CARDIOLOGY NEWS
117
Dabigatran and Rivaroxaban Confer Great Risk  
in Dialysis Patients
Dabigatran and rivaroxaban are eliminated through the 
kidneys, hence their use in dialysis patients is discouraged 
because these drugs can accumulate and cause inadvertent 
bleeding. Nevertheless, a steady increase of dabigatran and 
rivaroxaban use has been recorded among 29,977 hemodi-
alysis patients with atrial fibrillation in the USA, where 5.9% 
of anticoagulated dialysis patients are started on these new 
anticoagulants, with consequent higher risk of hospitalization 
or death from bleeding when compared with warfarin (rate 
ratio 1.48 for dabigatran, P=0.0001) and 1.38 for rivaroxaban, 
P=0.04). The risk of hemorrhagic death was even larger with 
dabigatran (rate ratio, 1.78; P=0.006) and rivaroxaban (rate 
ratio, 1.71; P=0.07) relative to warfarin. Differences in stroke 
and arterial embolism could not be detected in this study as 
there were too few events. The authors concluded that more 
dialysis patients are being started on dabigatran and rivaroxa-
ban, even when their use is contraindicated and there are no 
studies to support that the benefits outweigh the risks of these 
drugs in end-stage renal disease (Chan KE et al, Circulation 
2015;131:972-979).
TRA 2°P - TIMI 50 Trial: Vorapaxar in Patients  
With Diabetes Mellitus and Previous Myocardial 
Infarction Reduces CV Risk but Increases Bleeding
In patients with diabetes (DM) and prior MI (n=3623), 
barring those with prior TIA or stroke (whereby the drug is 
contraindicated), vorapaxar significantly reduced the primary 
end point (cardiovascular-CV death, MI, or stroke) (11.4% 
vs 14.3%; hazard ratio-HR, 0.73; P=0.002) with a number 
needed to treat to avoid 1 major CV event of 29. The incidence 
of bleeding was increased with vorapaxar (4.4% vs 2.6%; HR, 
1.60). However, net clinical outcome (efficacy and safety) was 
improved with vorapaxar (HR, 0.79). The authors concluded 
that in patients with previous MI and DM, vorapaxar added 
to standard therapy significantly reduced the risk of major CV 
events, albeit at a cost of increased bleeding (Cavender MA 
et al, Circulation 2015;131:1047-1053).
Reduced Cardiovascular and Mortality Risks in 
Elderly Medicare Patients with Atrial Fibrillation  
(AF) Treated With Dabigatran Compared  
to Warfarin, but Increased Major  
Gastrointestinal Bleeding Risk
Among 134 414 Medicare patients with 37 587 person-years 
of follow-up, the hazard ratios comparing dabigatran with 
warfarin were 0.80 for ischemic stroke; 0.34 for intracranial 
hemorrhage; 1.28 for major gastrointestinal (GI) bleeding; 0.92 
for acute MI; and 0.86 for death. In the subgroup of dabigatran 
75 mg bid, there was no difference in risk compared with war-
farin for any outcome except reduced intracranial hemorrhage. 
The authors concluded that dabigatran was associated with 
reduced risk of ischemic stroke, intracranial hemorrhage, and 
death and increased risk of major GI hemorrhage compared 
with warfarin in elderly patients with nonvalvular AF. These 
associations were most pronounced in patients treated with 
dabigatran 150 mg bid, whereas the lower dose of 75 mg bid 
was similar to warfarin except for a lower risk of intracranial 
hemorrhage (Graham DJ et al, Circulation 2015;131:157-164).
Icatibant, a Selective Bradykinin B2  
Receptor Antagonist, is Effective  
in ACE-Inhibitor–Induced Angioedema
All 27 patients with ACE-inhibitor–induced angioedema 
of the upper aerodigestive tract had complete resolution of 
edema with therapy. The median time to resolution was 8 
hours for those randomly assigned to 30 mg of subcutaneous 
icatibant, a selective bradykinin B2 receptor antagonist, as 
compared with 27.1 hours in those assigned to current off-label 
standard therapy (IV 500 mg prednisolone plus 2 mg clemas-
tine) (P=0.002), with 3 patients in the standard therapy group 
requiring rescue intervention with icatibant and prednisolone; 
1 patient required tracheotomy. More patients in the icatibant 
than in the standard-therapy group had complete resolution of 
edema within 4 hours (5 of 13 vs 0 of 14, P=0.02). The median 
time to the onset of symptom relief was shorter with icatibant 
than with standard therapy (2 vs 11.7 hours, P=0.03). The 
authors concluded that among patients with ACE-inhibitor–in-
duced angioedema, the time to complete resolution of edema 
was shorter with icatibant than with combination therapy with 
a glucocorticoid and an antihistamine (Bas M et al, N Engl J 
Med 2015;372:418-425).
Good Efficacy of a Device that Narrows  
the Coronary Sinus in Refractory Angina
A total of 104 patients with refractory (CCS class III or 
IV) angina and myocardial ischemia, who were not candi-
dates for revascularization, were randomized to implantation 
of a balloon-expandable, stainless steel, hourglass-shaped, 
coronary-sinus reducing device (creating a focal narrowing and 
increasing pressure in the coronary sinus, thus redistributing 
blood into ischemic myocardium) (treatment group, n=52) 
or to a sham procedure (control group, n=52). More (35% vs 
15%) patients in the treatment compared to the control group 
had an improvement of at least two CCS angina classes at 6 
months (P=0.02), or improvement of at least one CCS angina 
class (71% vs 42%; P=0.003). Quality of life was significantly 
improved in the treatment vs control group (P=0.03), with 
no significant between-group differences in improvement in 
exercise time or in the mean change in the wall-motion index 
by dobutamine echocardiography. At 6 months, 1 patient in 
the treatment group had a myocardial infarction (MI); in the 
control group, 1 patient died and 3 had an MI. The authors 
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concluded that implantation of the coronary-sinus reducing 
device was associated with significant improvement in symptoms 
and quality of life in patients with refractory angina who were 
not candidates for revascularization (Verheye S et al, N Engl 
J Med 2015;372:519-527). 
BEST Trial: Bypass Surgery (CABG)  
Superior to Second Generation  
(Everolimus-Eluting) Stents in Multivessel  
Coronary Artery Disease (CAD)
A total of 880 patients with multivessel CAD were rand-
omized to PCI with everolimus-eluting stents (n=438) or to 
CABG (n=442). At 2 years, the primary end point (death, MI, 
or target-vessel revascularization) occurred in 11% vs 7.9% 
in the 2 groups, respectively (P=0.32 for noninferiority). At 
longer-term follow-up (median, 4.6 years), the primary end-
point had occurred in 15.3% vs 10.6% (hazard ratio, 1.47; 
P=0.04). Rates of any repeat revascularization and spontaneous 
MI were significantly higher after PCI than after CABG. The 
authors concluded that among patients with multivessel CAD, 
the rate of major adverse cardiovascular events was higher 
among those who underwent PCI with use of everolimus-eluting 
stents than among those having CABG (Park S-J et al, N Engl 
J Med 2015;372:1204-1212). 
Clinical-Practice Registry Study Comparing  
Second Generation Stenting with Bypass Surgery:  
Similar Risk of Death but Higher Risk of MI  
and Repeat Procedures and Lower Risk  
of Stroke with PCI
At a mean follow-up of 2.9 years of 18,446 patients, 9223 
patients undergoing PCI with everolimus-eluting stents and 
9223 having CABG, PCI vs CABG had similar risk of death 
(3.1% vs 2.9% per year; hazard ratio-HR, 1.04; P=0.50), 
higher risks of MI (1.9% vs 1.1% per year; HR, 1.51; P<0.001, 
only for those with incomplete revascularization) and repeat 
revascularization (7.2% vs 3.1% per year; HR, 2.35; P<0.001), 
and a lower risk of stroke (0.7% vs 1.0% per year; HR, 0.62; 
P<0.001). The authors concluded that the risk of death with 
PCI was similar to that associated with CABG. PCI was 
associated with a higher risk of MI (among patients with 
incomplete revascularization) and repeat revascularization 
but a lower risk of stroke (Bangalore S et al, N Engl J Med 
2015;372:1213-1222). 
In-stent Restenosis Detected by Angiographic 
Surveillance in 10 004 patients is Predictive of 4-Year 
Mortality Even in Asymptomatic Patients 
Among 10 004 stented patients undergoing routine control 
angiography after 6-8 months, restenosis was detected in 2643 
(26.4%) patients. Of 702 deaths occurring during follow-up, 
218 occurred among patients with restenosis and 484 deaths in 
patients without restenosis (hazard ratio- HR: 1.19; P=0.03). 
Restenosis was an independent predictor of 4-year mortality; 
HR: 1.23; P=0.02). Other independent correlates of 4-year mor-
tality were age (for each 10-year increase, HR: 2.34; P <0.001), 
diabetes mellitus (HR: 1.68; P <0.001), current smoking habit 
(HR: 1.39; P=0.01), and left ventricular ejection fraction (for 
each 5% decrease, HR: 1.39; P <0.001). The authors concluded 
that the presence of restenosis at follow-up angiography after 
coronary stenting was predictive of 4-year mortality, even in 
patients that were asymptomatic. The evidence of restenosis 
provided prognostic information complementary to that pro-
vided by other clinical characteristics (age, gender, diabetes 
mellitus, smoking, previous by-pass surgery, ejection fraction). 
These findings suggest that newer-generation drug-eluting 
stents may have a meaningful impact on long-term mortality 
through the reduction in restenosis after coronary stenting 
(Cassesse S et al, Eur Heart J 2015;36:94-99).
Network Meta-Analysis: Effectiveness of PFO  
Closure Depends on the Device Used / PFO  
Closure With Ampatzer Occluder Appears  
Superior to Medical Therapy in Preventing  
Strokes in Patients with Cryptogenic Embolism
A network meta-analysis of 4 randomized trials (2963 pa-
tients with 9309 patient-years) including 3 devices (Amplatzer, 
STARFlex, and HELEX) indicated that patients allocated to 
PFO closure with Amplatzer were less likely to experience a 
stroke than patients allocated to medical therapy (rate ratio 
-RR 0.39), while no significant differences were found for 
the other devices. No significant differences were found for 
transient ischemic attack and death. The risk of new-onset 
atrial fibrillation was more pronounced for STARFlex (RR 
7.67), than Amplatzer (RR 2.14) and HELEX (RR 1.33), 
when compared with medical therapy. The authors concluded 
that network meta-analysis provided evidence in favour of 
percutaneous closure of PFO with one of the examined 
devices (Amplatzer) in patients with a history of cryptogenic 
stroke or embolism and a PFO (Stortecky S et al, Eur Heart 
J 2015;36:120-128).
ANSWER Study: AAI-DDD Changeover Mode  
to Minimize Ventricular Pacing (SafeR) Compared 
to DDD Mode did not Reduce Heart Failure (HF) 
Hospitalization or Atrial Fibrillation (AF)
A total of 650 patients (52% sinus node disease, 48% AV 
block) were randomized to SafeR (n=314) or DDD (n=318) 
mode. The SafeR mode showed a significant decrease in ven-
tricular pacing (VP) compared with DDD (11.5 vs 93.6%, P 
<0.0001 at 3 years). Deaths and syncope did not differ in the 
two groups. No significant difference was found in the time to 
event of the co-primary composite of hospitalization for HF, 
AF, or cardioversion, nor in the individual components. How-
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ever, SafeR showed a 51% risk reduction (RR) in experiencing 
cardiac death or HF hospitalization (hazard ratio-HR=0.49; 
P=0.02) and 30% RR in experiencing cardiovascular hospi-
talizations (HR=0.70; P=0.05). The authors concluded that 
SafeR vs DDD safely and significantly reduced VP with no 
effect on hospitalization for HF, AF, or cardioversion, but 
admitted that the favourable effect of SafeR-mediated VP 
prevention on HF outcomes warrants further investigation, 
as the combined clinical secondary outcome of cardiac death 
or HF hospitalization differed in favour of the SafeR group, 
with an observed borderline significant reduction in cardio-
vascular hospitalizations and shorter duration of hospital stay 
for these hospitalizations (Stockburger M et al, Eur Heart J 
2015;36:151-157).
Ibaraki Study: Presence of Atrial Premature  
Beats (APBs) in 12-Lead ECGs is Associated  
with Increased Risk of Cardiovascular (CV)  
Death and New-Onset Atrial Fibrillation (AF)  
in the General Population
Among 63,197 individuals (mean age, 58.8±9.9 years; 67.6% 
women) who participated in annual community-based health 
checkups, during a 14-year mean follow-up, in subjects with 
APBs, compared with those without APBs, the hazard ratio 
(HRs) of stroke death was 1.24 for men and 1.63 for women, 
of CV death 1.22 for men and 1.48 for women, and of all-cause 
death 1.08 for men and 1.21 for women. The presence of APBs 
at baseline was also a significant predictor of AF onset (HR 
4.87 for men and 3.87 for women). The authors concluded that 
the presence of APBs in 12-lead ECGs was a strong predictor 
of AF development, and associated with increased risk of CV 
death in the general population (Murakoshi N et al, Eur Heart 
J 2015;36:170-178). 
Analysis of 6563 Aspirin-Treated Patients  
in ACTIVE-A and AVERROES: Patients with  
Permanent AF are at a Higher Risk of Stroke 
Compared with Patients with Non-Permanent  
AF / in Deciding whether to Offer Anticoagulation  
to Low-Risk Patients, it May be Useful to Consider  
the Pattern of AF Occurrence
Among 6563 aspirin-treated patients with AF from the 
ACTIVE-A/AVERROES databases (mean age: 69±9.9 for 
paroxysmal, 68.6±10.2 for persistent, and 71.9±9.8 years for 
permanent AF (P <0.001), the CHA2DS2-VASc score was 
similar in patients with paroxysmal and persistent AF (3.1±1.4), 
but higher in permanent AF (3.6±1.5, P <0.001). Annual stroke 
rates were 2.1% for paroxysmal, 3% for persistent, and 4.2% 
for permanent AF, with hazard ratio of 1.83 (P <0.001) for 
permanent vs paroxysmal and 1.44 (P=0.02) for persistent vs 
paroxysmal. Age ≥75 years, gender, history of stroke or TIA, 
and AF pattern were independent predictors of stroke, with AF 
pattern being the second strongest predictor after prior stroke 
or TIA. The authors concluded that among non-anticoagulated 
AF patients, pattern of AF was a strong independent predic-
tor of stroke risk and may be helpful to assess risk/benefit for 
anticoagulant therapy in lower risk patients (Vanassche T et 
al, Eur Heart J 2015;36:281-288). 
ROCKET-AF Trial: Higher Risk of Death  
and Stroke in Persistent vs Paroxysmal Atrial 
Fibrillation (AF)
Of 14,062 patients in the ROCKET-AF trial, 11,548 
(82%) had persistent and 2,514 (18%) had paroxysmal AF. 
Patients with persistent AF were marginally older (73 vs 72, 
P=0.03), less likely female (39 vs 45%, P <0.0001), and more 
likely to have prior use of vitamin K antagonists (64 vs 56%, 
P <0.0001) compared with patients with paroxysmal AF. In 
patients randomized to warfarin, time in therapeutic range 
was similar (58 vs 57%, P=NS). Patients with persistent AF 
had higher rates of stroke or systemic embolism (2.18 vs 1.73 
events per 100-patient-years, P=0.048) and all-cause mortality 
(4.78 vs 3.52, P=0.006). Rates of major bleeding were similar 
(3.55 vs 3.31, P=NS). Rates of stroke or systemic embolism 
in both types of AF did not differ by treatment assignment 
(rivaroxaban vs warfarin). The authors concluded that patients 
with persistent AF have a higher risk of stroke and death 
compared with paroxysmal AF (Steinberg BA et al, Eur Heart 
J 2015;36:288-296).
The Swedish Atrial Fibrillation (AF)  
Cohort Study: Stroke Benefit from  
Anticoagulation, but Higher Risk of Bleeding  
in Patients with AF and Renal Failure
In a retrospective non-randomized study of Swedish health 
registers comprising 307,351 patients with AF, ischemic stroke 
occurred more often among 13,435 with prior diagnosis of renal 
failure (annual rate, 3.9% vs no renal failure, 2.9%), but this 
was related to concomitant comorbidities (hazard ratio -HR 
1.02). Adding renal failure to the established risk stratification 
(CHADS2 and CHA2DS2-VASc) did not improve predictive 
value. Renal failure was an independent risk factor for intrac-
ranial bleeding (HR: 1.27). Most patients with renal failure 
benefited from warfarin treatment, despite their high bleed-
ing risk. The incidence of the combined endpoint ischemic or 
hemorrhagic stroke or death was lower among those who used 
warfarin (HR: 0.76). The authors concluded that patients with 
AF and renal failure will probably benefit most from having 
same treatment as is recommended for other patients with AF, 
by careful considerations of net benefit, optimal management 
of other risk factors for stroke and bleeding, and rigorous 
control of INR. Adding additional points for renal failure to 
the CHA2DS2-VASc score did not improve predictive value 
(Friberg L et al, Eur Heart J 2015;36:297-306). 
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Denmark Cohort Study: Thromboembolic  
Risk Beyond 3 Months after Radiofrequency  
Ablation (RFA) of AF is Relatively Low 
During a median follow-up of 3.4 years of 4050 patients 
(median age 59.5, 26.5% females) undergoing first-time RFA, 
71 (1.8%) thromboembolism cases were identified, where 
incidence rates with and without oral anticoagulation (OAC) 
were 0.56 and 0.64, respectively. Discontinuation of OAC 
remained insignificant (hazard ratio-HR 1.42) in multivari-
able analysis. Beyond 3 months after RFA, 87 (2.1%) serious 
bleedings occurred (incidence rates with and without OAC 
0.99 and 0.44, respectively). OAC therapy was significantly 
associated with serious bleeding risk (HR 2.05). In an age- and 
gender-matched cohort of 15,848 non-ablated AF patients 
receiving rhythm-control therapy, thromboembolic rates with 
and without OAC were 1.34 and 2.14, respectively. The authors 
concluded that thromboembolic risk beyond 3 months after 
RFA was relatively low compared with a matched non-ablated 
AF cohort. With cautious interpretation due to low number 
of events, serious bleeding risk associated with OAC seems 
to outweigh the benefits of thromboembolic risk reduction. 
The CHA2DS2-VASc score may not be an appropriate tool for 
thromboembolic risk stratification in this population (Karasoy 
D et al, Eur Heart J 2015;36:307-315). 
MADIT-CRT Trial: in Patients with LBBB, 
Biventricular (BIV) Pacing >90% Confers  
Benefit of Cardiac Resynchronization  
Therapy-Defibrillator (CRT-D) in Heart Failure  
(HF)/Death when Compared with Implantable 
Cardioverter Defibrillator (ICD) 
The threshold of BIV pacing percentage needed for CRT-
D to be superior to ICD on the end-point of heart failure 
(HF) or death was estimated in 1219 left bundle branch block 
(LBBB) patients in the MADIT-CRT trial (NYHA class I/II 
HF patients in sinus rhythm). In multivariable analyses, no 
difference was seen in the risk of HF/death between ICD and 
CRT-D patients with BIV pacing ≤90% (HR=0.78, P=NS), 
and with increasing BIV pacing the risk of HF/death was de-
creased (CRT-D BIV 91–96% vs ICD: HR=0.63, P=0.024; 
and CRT-D BIV ≥97% vs ICD: HR=0.32, P <0.001). The risk 
of death alone was reduced by 52% in CRT-D patients with 
BIV ≥97% (HR=0.48, P<0.016), when compared with ICD 
patients. Within the CRT-D group, for every 1% increase in 
BIV pacing, the risk of HF/death and death alone significantly 
decreased by 6 and 10%, respectively. The authors concluded 
that in patients with LBBB, BIV pacing >90% was associated 
with a benefit of CRT-D in HF/death when compared with ICD 
patients. Also, BIV pacing ≥97% was associated with an even 
further reduction in HF/death, a significant 52% reduction in 
death alone, and increased reverse remodelling. Physicians 
should be aware of patients with suboptimal BIV pacing to 
implement preventive and optimizing measures to improve 
outcome and prognosis in these patients (Ruwald A et al, Eur 
Heart J 2015;36:440-448).
Systemic Review & Meta-analysis: Thrombolysis  
is Associated with a Significant Reduction of Mortality 
in Patients with Pulmonary Embolism (PE),  
but this Reduction is not Statistically Significant  
after Exclusion of Studies with High-Risk PE, While  
it is Associated with an Increase in Fatal, Intracranial, 
or Major Hemorrhage
According to meta-analysis of 15 randomized trials compar-
ing thrombolytic therapy plus anticoagulation with anticoagu-
lation alone in 2057 patients with acute pulmonary embolism 
(PE), thrombolytic therapy was associated with a significant 
reduction of overall mortality (OR; 0.59). This reduction was 
not statistically significant after exclusion of studies including 
high-risk PE (OR; 0.64). Thrombolytic therapy was associated 
with a significant reduction in the combined endpoint of death 
or treatment escalation (OR: 0.34), PE-related mortality (OR: 
0.29) and PE recurrence (OR: 0.50). Major hemorrhage (OR; 
2.91) and fatal or intracranial bleeding (OR: 3.18) were signifi-
cantly more frequent among patients receiving thrombolysis. 
The authors concluded that thrombolytic therapy reduces total 
mortality, PE recurrence, and PE-related mortality in patients 
with acute PE, albeit at increased risk of major and fatal or 
intracranial hemorrhage. The decrease in overall mortality is, 
however, not significant in hemodynamically stable patients 
with acute PE (Marti C et al, Eur Heart J 2015;36:605-614). 
CONFIRM-HF: Beneficial Effects of Long-term 
Intravenous (IV) Iron Therapy in Patients with 
Symptomatic Heart Failure and Iron Deficiency
A total of 304 heart failure (HF) patients with left ven-
tricular ejection fraction ≤45%, elevated natriuretic pep-
tides, and iron deficiency (ferritin <100 ng/mL or 100–300 
ng/mL if transferrin saturation <20%), were randomized 
1:1 to IV iron, as ferric carboxymaltose (FCM, n=152) or 
placebo (saline, n=152) for 52 weeks. Treatment with FCM 
significantly prolonged 6-min-walk-test (6MWT) distance at 
Week 24 (difference FCM vs placebo: 33±11 m, P=0.002). 
The treatment effect of FCM was consistent in all subgroups 
and was sustained to Week 52 (difference FCM vs placebo: 
36±11 m, P<0.001). Throughout the study, an improvement in 
NYHA class, patient global assessment, quality of life (QoL), 
and fatigue score in patients treated with FCM was detected 
with statistical significance observed from Week 24 onwards. 
Treatment with FCM was associated with a significant reduction 
in the risk of hospitalizations for worsening HF (hazard ratio: 
0.39, P=0.009). The number of deaths (FCM: 12, placebo: 14 
deaths) and the incidence of adverse events were comparable 
between groups. The authors concluded that treatment of 
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symptomatic, iron-deficient HF patients with FCM over a 
1-year period resulted in sustainable improvement in functional 
capacity, symptoms, and QoL and may be associated with risk 
reduction of hospitalization for worsening HF (Ponikowski P 
et al, Eur Heart J 2015;36:657-668).
ABSORB II Trial: Stents with Bioresorbable  
Scaffold Had 1-year Clinical Outcome Similar  
to Metallic Stents
A total of 501 patients undergoing percutaneous coronary 
intervention were randomly assigned (2:1 ratio) to the biore-
sorbable scaffold stent group (everolimus-eluting bioresorb-
able scaffold) (335 patients, 364 lesions) or the metallic stent 
group (everolimus-eluting metallic stent) (166 patients, 182 
lesions). Acute lumen gain was lower for the bioresorbable 
scaffold. At 1 year, cumulative rates of first new or worsening 
angina were lower (22%) in the bioresorbable scaffold group 
(vs 30% in the metallic stent group; p=0·04), whereas per-
formance during maximum exercise and angina status were 
similar. Three patients in the bioresorbable scaffold group had 
stent thromboses, compared with no patients in the metallic 
stent group. There were 5% major cardiac adverse events in 
the bioresorbable scaffold group compared with 3% events 
in the metallic stent group, with the most common events 
being myocardial infarction and need for target-lesion revas-
cularisation. The authors concluded that everolimus-eluting 
bioresorbable scaffold showed similar 1-year clinical outcomes 
to the everolimus-eluting metallic stent (Serruys PW et al, 
Lancet 2015;385:43-54).
RUTHERFORD-2: In Patients with Heterozygous 
Familial Hypercholesterolemia, PCSK9 Inhibition 
With Evolocumab was Well Tolerated and Yielded 
Rapid 60% Reductions in LDL Cholesterol  
Compared with Placebo
A total of 331 patients with heterozygous familial hyper-
cholesterolemia were randomly assigned to 4 treatment groups: 
evolocumab 140 mg every 2 weeks (n=111), evolocumab 420 
mg monthly (n=110), placebo every 2 weeks (n=55), or placebo 
monthly (n=55). Compared with placebo, evolocumab at both 
dosing schedules led to a significant reduction in mean LDL 
cholesterol at week 12 (every-2-weeks dose: 59.2% reduction, 
monthly dose: 61.3% reduction; both p<0.0001) and at the 
mean of weeks 10 and 12 (60.2% reduction and 65.6% reduc-
tion; both p<0.0001). Evolocumab was well tolerated, with 
rates of adverse events similar to placebo. The most common 
adverse events occurring more frequently in the evolocumab-
treated patients were nasopharyngitis (9% vs 5%) and muscle-
related adverse events (5% vs 1%). The authors concluded that 
in patients with heterozygous familial hypercholesterolemia, 
evolocumab administered either 140 mg every 2 weeks or 420 
mg monthly was well tolerated and yielded rapid 60% reduc-
tions in LDL cholesterol compared with placebo (Raal FJ et 
al, Lancet 2015;385:331-340).
TESLA Part B Trial: Inhibition of PCSK9 with 
Evolocumab in Patients with Homozygous Familial 
Hypercholesterolemia on Lipid-Lowering Therapy 
and not on Apheresis, Significantly Reduced LDL 
Cholesterol Compared with Placebo
Patients (N=49), aged ≥12 years, with homozygous familial 
hypercholesterolemia, on stable lipid-regulating therapy for 
at least 4 weeks, and not receiving lipoprotein apheresis, were 
randomly assigned (2:1 ratio) to receive subcutaneous evo-
locumab 420 mg (n=33) or placebo (n=16) every 4 weeks for 
12 weeks. Compared with placebo, evolocumab significantly 
reduced LDL cholesterol at 12 weeks by 30.9% (p<0.0001). 
Adverse events occurred in 10 (63%) of 16 patients in the 
placebo group and 12 (36%) of 33 in the evolocumab group. 
No serious clinical or laboratory adverse events occurred, 
and no anti-evolocumab antibody development was detected 
during the study. The authors concluded that in patients with 
homozygous familial hypercholesterolemia, evolocumab was 
well tolerated and significantly reduced LDL cholesterol com-
pared with placebo (Raal FJ et al, Lancet 2015;385:341-350). 
International Carotid Stenting Study (ICSS)  
Trial: Long-term Outcomes Similar After Stenting  
or Endarterectomy for Treatment of Symptomatic 
Carotid Stenosis 
A total of 1710 patients with symptomatic carotid steno-
sis were randomly assigned to open treatment with stenting 
(n=855) or endarterectomy (n=858) and followed up for a 
median of 4.2 years. The number of fatal or disabling strokes 
(52 vs 49) and cumulative 5-year risk did not differ between 
the stenting and endarterectomy groups (6.4% vs 6.5%; hazard 
ratio -HR 1.06, p=NS). Any stroke was more frequent in the 
stenting group than in the endarterectomy group (119 vs 72 
events (p=0.04), but were mainly non-disabling strokes. The 
authors concluded that long-term functional outcome and 
risk of fatal or disabling stroke are similar for stenting and 
endarterectomy for symptomatic carotid stenosis (Bonati LH 
et al, Lancet 2015;385:529-538).
SIMPLE Study: Routine Defibrillation Testing (DFT) 
at the Time of ICD Implantation is Well Tolerated,  
but does not Improve Shock Efficacy or Reduce 
Arrhythmic Death 
A total of 1253 patients having an implantable cardioverter 
defibrillator (ICD) implantation were randomly assigned to 
defibrillation testing (DFT) and 1247 to no-testing, and followed 
up for a mean of 3.1 years. The primary outcome of arrhythmic 
death or failed appropriate shock occurred in fewer patients 
(7% per year) in the no-testing group than patients who did 
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receive it (8% per year; HR 0.86). The first safety composite 
outcome occurred in 5.6% of patients with no-testing and in 
6.5% of patients with DFT (p=NS). The second, pre-specified 
safety composite outcome, which included only events most 
likely to be directly caused by testing, occurred in 3.2% of 
patients with no-testing and in 4.5% with DFT, p=0.08. Heart 
failure needing intravenous treatment with inotropes or diuret-
ics was the most common adverse event (2% in both groups). 
The authors concluded that routine DFT at the time of ICD 
implantation is generally well tolerated, but does not improve 
shock efficacy or reduce arrhythmic death (Healey J et al, 
Lancet 2015;385:785-791).
Systematic Review and Meta-analysis: Extended 
Duration Dual Antiplatelet Therapy is not Associated 
with a Difference in Risk of Total, Cardiovascular 
(CV), or non-CV Mortality
Including the Dual Antiplatelet Therapy (DAPT) Study, 
which showed that continuation of dual antiplatelet therapy 
beyond 12 months after coronary stenting was associated with 
an unexpected increase in non-CV death, 14 trials were iden-
tified that randomly assigned 69,644 participants to different 
durations of dual antiplatelet therapy. Compared with aspirin 
alone or short duration dual antiplatelet therapy (≤6 months), 
continued treatment was not associated with a difference in 
all-cause mortality (hazard ratio -HR 1.04; p=NS). Similarly, 
CV (HR 1.01) and non-CV mortality (HR 1.04; p=NS) were 
no different with extended duration versus short duration dual 
antiplatelet therapy or aspirin alone. The authors concluded 
that extended duration dual antiplatelet therapy was not associ-
ated with a difference in the risk of all-cause, CV, or non-CV 
death compared with aspirin alone or short duration dual an-
tiplatelet therapy (Elmariah S et al, Lancet 2015;385:792-798). 
Cardiac Screening of Low-Risk Adults with Functional 
Stress Testing: No Evidence that it Improves Patient 
Outcomes, while it Confers Increased Costs and 
Potential Harms
Literature review indicates that cardiac screening in adults 
with resting or stress electrocardiography, stress echocardiog-
raphy, or myocardial perfusion imaging has not been shown to 
improve patient outcomes. Contrariwise, it may be associated 
with potential harms due to false-positive results as it can lead 
to subsequent, potentially unnecessary tests and procedures. It 
is particularly inefficient in adults at low risk for coronary artery 
disease due to low prevalence and predictive values of testing 
in this population and low likelihood that positive findings will 
affect treatment decisions. It is preferable that clinicians focus 
on strategies that reduce cardiovascular risk by modifying and 
managing risk factors, such as smoking, diabetes, hypertension, 
hyperlipidemia, and obesity, while encouraging exercise and 
healthy diet. The authors conclude that clinicians should not 
screen for cardiac disease in asymptomatic, low-risk adults with 
resting or stress electrocardiography, stress echocardiography, 
or stress myocardial perfusion imaging (Chou R et al, Ann 
Intern Med 2015;162:438-447).
Population-Based Case-Control Study: Association of 
Amiodarone Use and Risk of Acute Pancreatitis
According to a Taiwanese case-control study involving 4986 
subjects (aged 20–84) with a first episode of acute pancreatitis 
and 19,944 matched subjects without acute pancreatitis, cur-
rent use of amiodarone was positively associated with acute 
pancreatitis (odds ratio 5.21). There was no significant as-
sociation between recent or past amiodarone use and acute 
pancreatitis. The authors concluded that patients with current 
use of amiodarone are at an increased risk of acute pancreatitis 
(Lai S et al, Heart Rhythm 2015;12:163-166).
Permanent His-Bundle Pacing is Feasible in Routine 
Clinical Practice
With use of the Select Secure (model 3830) pacing lead via 
a guiding catheter, His bundle pacing (HBP) was attempted in 
94 consecutive patients, while 98 patients underwent right ven-
tricular pacing (RVP). HBP was successful in 75 patients (80%) 
with similar fluoroscopy time, albeit higher pacing threshold 
compared with the RVP group (1.35±0.9 V vs 0.6±0.5 V at 
0.5 ms; P <0.001) that remained stable over a 2-year follow-up 
period. In patients with >40% ventricular pacing (>60% of 
patients), heart failure hospitalization was significantly reduced 
in the HBP group (2% vs 15%; P=0.02), with no difference in 
mortality (13% vs 18%; P=NS). The authors concluded that 
permanent HBP without a mapping catheter was successfully 
achieved in 80% of patients, displaying higher pacing threshold, 
but achieving better clinical outcomes (Sharma PS et al, Heart 
Rhythm 2015;12:305-312).
Implantable Devices (Defibrillators-ICDs/Pacemakers-
PPMs) Exacerbate Tricuspid Regurgitation (TR) which 
Confers Higher Mortality Risk
Among 1,596 patients (aged 60±10 years, 61% men) who 
had cardiac devices implanted (62% ICDs or CRT-D; 38% 
PPMs), the prevalence of grade 3 or 4+ TR increased from 
27% to 31% by 1 month and to 35% at 4 years. Device type 
(ICD vs PPM) and the number of leads placed did not have an 
effect on post-procedural TR. Right ventricular systolic pres-
sure did not change over time. One-year and 5-year survival 
was 93% and 73%, respectively. Post-procedural TR was an 
independent risk factor for late death (P <0.05). The authors 
concluded that cardiac device implantation was associated with 
a small but significant increase in the prevalence of moderate 
and severe TR, both acutely and chronically after implanta-
tion, similar for both ICD and PPM placement, not related 
to the number of leads implanted. Postimplantation TR was 
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associated with a higher risk of mortality (Al-Bawardy R et 
al, Pacing Clin Electrophysiol 2015;38:259-266).
Systematic Review and Meta-Analysis: Blood Pressure 
Lowering Improves Survival in Type 2 Diabetes
Analysis of 40 randomized controlled trials (100,354 partici-
pants) of blood pressure (BP) lowering in diabetics indicated 
that each 10-mm Hg lower systolic BP was associated with a 
significantly lower risk of mortality (relative risk -RR, 0.87); 
absolute risk reduction (ARR) in events per 1000 patient-
years (3.16), cardiovascular events (RR, 0.89; ARR, 3.90), 
coronary artery disease (RR, 0.88; ARR, 1.81), stroke (RR, 
0.73; ARR, 4.06), albuminuria (RR, 0.83; ARR, 9.33), and 
retinopathy (RR, 0.87; ARR, 2.23). The associations between 
BP-lowering treatments and outcomes were not significantly 
different, irrespective of drug class, except for stroke and heart 
failure. The authors concluded that among patients with type 
2 diabetes, BP lowering was associated with improved clinical 
outcomes with lower RRs observed among those with baseline 
BP of ≥140 mm Hg (Emdin CA et al, JAMA 2015;313:603-615). 
Reperfusion Success is Influenced by Thrombus 
Burden, which May be Improved by Mesh-Covered 
Stents in Acute Myocardial Infarction 
Among 433 patients with ST elevation myocardial infarction 
(STEMI) randomized to the mesh-covered MGuard stent vs a 
control bare-metal or drug-eluting stent, angiographically vis-
ible thrombus was identified in 383 patients (88.5%). Lesions 
with large thrombus were treated more frequently with manual 
aspiration (80.8% vs 65.8%, p=0.0009) and longer and larger 
stents. Percutaneous coronary intervention (PCI) of lesions with 
large thrombus burden had more thrombotic complications 
(30.6% vs 15.9%, p=0.0007) and reduced angiographic success 
(80.3% vs 91.1%, p=0.003). In lesions with large thrombus, 
the MGuard stent was more effective than control stents in 
achieving TIMI-3 flow (87.9% vs 74.5%, p=0.02) and tended to 
result in less slow flow or no reflow (8.8% vs 17.6%, p=0.07). 
The authors concluded that reperfusion success is reduced 
after primary PCI in lesions with large thrombus burden, an 
outcome that may be improved by the MGuard stent (Costa 
RA et al, Am J Cardiol 2015;115;161-166).
Obstructive Sleep Apnea (OSA) is a Predictor of Stroke 
in Patients With Atrial Fibrillation (AF)
Of 5,138 patients screened for obstructive sleep apnea 
(OSA), 402 (7.7%) had AF and 332 (6.4%) constituted the 
study population, whereby the occurrence of first-time stroke 
was 22.9%. Ischemic stroke was more common in patients with 
OSA (25.4% vs 8.2%, p=0.006; odds ratio 3.65). Subgroup 
analysis showed significantly higher rates of stroke in patients 
with CHADS2 scores of 0 and CHA2DS2-VASc scores of 0 and 
1 and co-morbid OSA. The authors concluded that OSA in 
patients with AF is an independent predictor of stroke (Yaranov 
DM et al, Am J Cardiol 2015;115:461-465).
Important Review and Other Articles 
Central sleep apnea in heart failure (Costanzo MR et al, 
J Am Coll Cardiol 2015;65:72-84), Remote ischemic precon-
ditioning (Heusch G et al, J Am Coll Cardiol 2015; 65:177-
195), Substrate modification for AF ablation (Kottkamp H 
et al, J Am Coll Cardiol 2015;65:196-206), Device-detected 
AF (Chen-Scarabelli C et al, J Am Coll Cardiol 2015;65:281-
294), Hyponatremia in acute heart failure (Verbrugge FH 
et al, J Am Coll Cardiol 2015;65: 480-492), Sudden death in 
the older athlete (Chugh SS & Weiss JB, J Am Coll Cardiol 
2015;65:493-502), Revascularization in severe LV dysfunction 
(Velazquez EJ & Bonow RO, J Am Coll Cardiol 2015;65:281-
294), The myth of the “vulnerable plaque” (Arbab-Zadeh A 
& Fuster V, J Am Coll Cardiol 2015;65:846-855), Peripheral 
artery disease (Patel MR et al, J Am Coll Cardiol 2015;65:931-
941), Angiotensin receptor antagonism-neprilysin inhibitor 
therapy in heart failure (Braunwald E, J Am Coll Cardiol 
2015;65:1029-1041), Dietary sodium (Farquhar WB et al, J 
Am Coll Cardiol 2015;65:1042-1050), Secondary (functional) 
mitral regurgitation (Asgar AW et al, J Am Coll Cardiol 
2015;65:1231-1248), Porcelain aorta (Abramowitz Y et al, 
Circulation 2015;131:827-836), AHA statement on secondary 
prevention after coronary bypass (Kulik A et al, Circulation 
2015;131:927-964), Left atrial appendage occlusion (Whitlock 
RP et al, Circulation 2015;131:756-761), Disorders of plasma 
sodium (Sterns RH, N Eng J Med 2015; 372:55-65), Carotid 
artery stenting (Cremonesi A et al, Eur Heart J 2015;36:13-21), 
Air pollution and cardiovascular disease (Newby DE et al, Eur 
Heart J 2015;36:83-93), Myocardial infarction with no obstruc-
tive coronary atherosclerosis (Niccoli G et al, Eur Heart J 2015; 
36;475-481), Ularitide for treatment of acute heart failure 
(Anker SD et al, Eur Heart J 2015;36:715-723), Cryptogenic 
stroke and silent atrial fibrillation (Glotzer TV & Ziegler PD, 
Heart Rhythm 2015;12:234–241), Early repolarization syndrome 
(Mahida S et al, Heart Rhythm 2015;12:242-249).
